ReviewThe Journal of experimental medicine2019
Modulating inflammation for cancer therapy.
Review in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- The prognostic and clinicopathological value of HALP score in non-small cell lung cancer.Frontiers in immunology · 2025Pooled it
- The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review.International journal of biological sciences · 2021Pooled it
- The U-shaped correlation between the systemic immune-inflammation index and all-cause and cardiovascular mortality in hyperlipidemic patients: findings from NHANES 1999-2018.Annals of medicine · 2026Article
- A Double-Thiadiazole-Derived Fluorescent Probe for the Cyclooxygenase-2 Detection in Colorectal Tumor-Inflammation Interaction.Journal of fluorescence · 2026Article
- Epidermal PPARγ Signaling as a Suppressor of Toll-like Receptor-Mediated Inflammation and Fibrosis: Relevance to Cutaneous Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- Relationship Between IL6/IL10 Serum Concentrations and Organ Function in Critically Ill Patients Based on Sepsis: A Prospective Study.Immunity, inflammation and disease · 2026Article
- The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications.Journal of hematology & oncology · 2026Review
- Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest.Cancer cell · 2026Article
- Tumor Microenvironment Onmyoji: Cytokines with Dual Protumor and Antitumor Roles.Cancer communications (London, England) · 2026Review
- Visual screening and efficacy evaluation of high-performance fluorescent probe DAF-FM in esophagitis cancer transformation.World journal of gastrointestinal surgery · 2025Article
- Review
- From exposure to oncogenesis: a review on the multifaceted roles of microplastics in tumor initiation and progression.Journal of translational medicine · 2025Review
- Inflammatory burden index predicts long term mortality in a nationally representative population from NHANES.Scientific reports · 2025Article
- Anti-Inflammatory Potential of Essential Oil from the Heart-Wood of the Folk Medicinal TreeInternational journal of molecular sciences · 2025Article
- The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy.ESMO gastrointestinal oncology · 2025Article
- Age Difference in the Connection Between Systemic Inflammatory Response and Metabolic Syndrome.The Journal of clinical endocrinology and metabolism · 2025Article
- Role of Oxidative Stress in the Occurrence, Development, and Treatment of Breast Cancer.Antioxidants (Basel, Switzerland) · 2025Review
- Inflammatory markers predict efficacy of immunotherapy in advanced non-small cell lung cancer: a preliminary exploratory study.Discover oncology · 2025Article
- Survival in stage IV non-small cell lung cancer patients based on radiation dose to immune cells: a retrospective analysis.Frontiers in oncology · 2025Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A link between chronic inflammation and development of tumors is well established. Moreover, it has become evident that tumorigenesis is not a cell autonomous disease, and an inflammatory microenvironment is a prerequisite of basically all tumors, including those that emerge in the absence of overt inflammation. This knowledge has led to the development of anti-inflammatory concepts to treat and prevent cancer. In contrast, immunotherapies, in particular checkpoint inhibitors, representing the most significant progress in the therapy of several malignancies depend on the presence of a pro-inflammatory "hot" environment. Here, we discuss pro- and anti-inflammatory concepts for the treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.